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Introduction
Factor VIII (FVIII) is a plasma glycoprotein that
functions as a cofactor for the serine protease factor
IXa in the proteolytic activation of factor X to Xa.
Although FVIII is synthesized as a single chain, it
circulates in plasma as a heterodimer. The chains can
be dissociated by EDTA, indicating that they are kept
together by metal ions1.
The non-covalent heterodimer contains a heavy
chain (HCh), with a molecular weight between 90 to
200 kDa (A1-A2-B domains), and a light chain (LCh),
with a molecular weight of 80 kDa (A3-C1-C2
domains).
FVIII plays an important role in the intrinsic
pathways of the blood coagulation cascade. It
circulates as an inactive pro-cofactor in complex with
von Willebrand factor (vWF). Thrombin is the
principal physiological activator of FVIII. This
protease cleaves the protein at sites in both the HCh
and the LCh. Activated FVIII (FVIIIa) is a
heterotrimer of 50, 43 and 73 kDa subunits, which
are required for procoagulant activity2,3.
FVIII occurs in human plasma in very low
concentrations of about 100-200 ng/mL,
corresponding to one unit of FVIII per mL4.
Insufficient levels or the total absence of this protein
in the bloodstream lead to coagulation disorders,
widely known as haemophilia A2,3. This is a severe
bleeding disorder, which results from a defect or a
deficiency in FVIII. Haemophilia A is an X-linked
disease caused by defects in the expression or function
of the plasma glycoprotein FVIII5-7. Maintenance of
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normal levels of FVIII in the circulation is dependent
on its formation of a complex with vWF. FVIII and
vWF are assembled in a tight non covalent complex
which is essential for its stability in the plasma.
Patients with severe von Willebrand disease, where
vWF is deficient or where the binding between FVIII
and vWF is impaired, have a secondary deficiency of
FVIII2,3,8. When FVIII is bound to vWF, a stable
association of its HCh and LCh is maintained8-9. von
Willebrand factor also protects FVIII from cleavage
by activated FX and from protein C-catalyzed
degradation2,10,11.
The clinical manifestations of haemophilia A are
categorized with respect to the severity of FVIII
deficiency. FVIII activity levels of 5-25% are
associated with a mild disease state, 1-5% as moderate,
and less than 1% as severe12.
Severe haemophiliacs may have spontaneous
haemorrhages, requiring therapy two to four times
monthly13.
Haemophilic patients are at present treated with
plasma-derived FVIII (pdFVIII) or recombinant FVIII
(rFVIII), to correct their clotting defciency14,15.
Bleeding episodes are managed by administration of
FVIII-rich plasma cryoprecipitate or commercial
preparations of lyophilised FVIII concentrates1, which
are prepared either from human plasma or by
recombinant technology. In the case of plasma
prepared FVIII, viral safety is an essential requirement
and the purification process should inactivate both
enveloped and non-enveloped viruses. Solvent-
detergent and heat treatment are frequently used to
inactivate both viruses. According to literature data,
these treatments could result in undesired effect such
as: (a) increase of the antigenic properties of the
injected material that may induce formation of
inhibitory antibodies (Abs) in patients with severe
haemophilia A9-11; (b) increase of high molecular
weight (HMW) aggregates which may interfere with
the complete dissolution of the lyophilised FVIII
concentrates, when properly reconstituted. Therefore
the European Pharmacopoeia is modifying the FVIII
monograph, allowing the use of a filter, provided in
the package, to eliminate small flakes or particles16.
Regardless of the grade of purity, all FVIII
concentrates and especially plasma derived
concentrates could present formation of HMW
aggregates, having variable solubility, even if the
formation mechanism and aggregates composition can
be different. Nowadays it is not known if virus
inactivation processes may induce protein alterations
as well, as pdFVIII may contain impurities or
contaminants.
In this study, by using monodimensional gel
electrophoresis (SDS-PAGE) and Mass Spectrometry,
we revealed in Beriate® the presence of galectin 3
binding protein which coeluted with truncated form of
FVIII, inter-alfa globulin and, in Emoclot®  alfa 1
microglobulin, IGHM that could be considered as
contaminants.
Materials and method
Commercially-available pdFVIII concentrates
were used in this study. Materials consisted of Beriate®
1000UI/10mL (Aventis Behring) batch 81865011E
and Emoclot® 1000 UI/10mL batch KA0805
(Kedrion), both  products were reconstituted according
to the manufacturers' instructions.
Sample preparation
Protein concentration was estimated by the
Bradford method. 40 µg of samples were precipitated
with 80% acetone for 2h at –20 °C.
The sample was centrifuged at 14 000 rpm for
12 min, the supernatant was removed and the pellet
was air dried.  The pellets were suspended in 100 μL
of sample buffer and were incubated for 20 min in
100 mM DTT, 12% sucrose, 0.6% urea, 50 mM Tris-
HCl pH 6.8, 0.01% bromophenol blue at room
temperature.
SDS-PAGE
SDS-PAGE was performed according to
Laemmli's17 procedure under reducing conditions.
Reagents for electrophoretic analyses were obtained
from Bio-Rad. The  experiment was performed on a
12% , 11%, 9% and 7.5% acrylamide gel, in a chamber
with the following dimension 12x16x18 cm. The
second electrophoresis gel was performed at 7.5%
using a chamber with the following dimension
29x32x17 cm. A Protean II Bio-Rad (Hercules, CA,
USA) electrophoresis system (1803160 mm, 0.75 mm
thick) was used for the first dimension. Gels were fixed
and stained for 30 min in a 5:1:4 (v/v) methanol-
glacial acetic acid-water mixture. Protein bands were
stained with Coomassie Brilliant Blue R-250.
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In-gel-digestion
Bands from the monodimensional gel were carefully
excised and subjected to in-gel trypsin digestion according
to Shevchenko et al.18 with minor modifications.
The gel pieces were swollen in a digestion buffer
containing 50 mM NH4HCO3 and 12.5 ng/μL trypsin
(modified porcine trypsin, sequencing grade, Promega,
Madison, WI) in an ice bath. After 30 min, the supernatant
was removed and discarded, 20 μL of 50 mM NH4HCO3
were added to the gel pieces, and digestion was allowed
to proceed at 37  °C overnight. The supernatant containing
tryptic peptides was dried by vacuum centrifugation.
RP-nanoHPLC mass spectrometry
Prior to mass spectrometric analysis, the peptide
mixtures were re-dissolved in 10 μL of 5% FA (formic
acid). Peptide Sequencing was performed by
Nano-RP-HPLC-ESI-MS/MS. Peptide mixtures were
separated using a nano flow-HPLC system (Ultimate;
Switchos; Famos; LC Packings, Amsterdam, The
Netherlands). A sample volume of 10 μL was loaded
through the autosampler onto a homemade 2 cm fused
silica precolumn (75 μm i.d.; 375 μm o.d.; Reprosil
C18-AQ, 3 μm, Ammerbuch- Entringen, Germany)
at a flow rate of 2 μL/min. Sequential elution of
peptides was accomplished using a flow rate of 200
nL/min and a linear gradient from Solution A (2%
acetonitrile; 0.1% formic acid) to 50% of Solution B
(98% acetonitrile; 0.1%formic acid) in 40 min over
the precolumn in-line with a homemade 10-15 cm
resolving column (75 μm i.d.; 375 μmo.d.; Reprosil
C18-AQ, 3 μm, Ammerbuch-Entringen). Peptides
were eluted directly into a high capacity ion trap
(model HCTplus Bruker-Daltonik, Germany).
Capillary voltage was 1.5-2 kV and a dry gas flow
rate of 10 L/min was used with a temperature of
200 °C. The scan range used was from 300 to 1800 m/
z. Protein identification was performed by searching in
the National Center for Biotechnology Information
nonredundant (NCBInr) database using the MASCOT
program (http://www. matrixscience.com). The
following parameters were adopted for database
searches: complete carbamidomethylation of cysteines,
partial oxidation of methionines, peptide mass tolerance
(1.2 Da, fragment mass tolerance (0.9 Da and missed
cleavages 2. For positive identification, the score of the
result of [-10 × Log(P)] had to be over the significance
threshold level (P< 0.05).
Results
Two commercially-available preparations of
plasma FVIII concentrates Beriate® and Emoclot ®
were examined to determine eventual impurities
and/or contaminants. To this regard, SDS-PAGE was
used for protein separation, and mass spectrometry
for protein identification. Figure 1 compares the mini
gel electrophoretic separation pattern of pdFVIII from
two different manufacturers: Emoclot® and Beriate®.
We use different concentrations of acrylamide, ranging
from 7.5% to 12 % (see Figure 1 A-D) and mini gel
to set up the best condition.  As shown in fig. 1, best
results were obtained by using acrylamide at 7,5%.
Figure 1 - Mini gel SDS PAGE  of two pdVIII preparations:
Emoclot ® 1000 UI/10 mL batch KA0805
Kedrion and Beriate®  P1000 batch 81865011E
CLS Behring .
Samples are reduced according  to Laemmli's17
method and are analysed at different
concentration of acrilamide  a) 7,5% b) 9% c)
11% d) 12%.
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Figure 2 shows a new large gel-electorophoresis SDS
PAGE performing at 7.5% acrylamide. We apply mass
spectrometry to identify proteins, by cutting bands
from e SDS-PAGE of Beriate® and Emoclot® (Figure 2).
This avoided any further manipulation of samples.
Table I reports the identification spots numbered
as in Figure 2.
The most abundant proteins are in the spot 1 and 2
for both Emoclot ® and Beriate®. They contain vWF
as a predominant protein with 49 recognized peptides
covering the 17% of sequence. The percentage excess
of vWF over pdFVIII is more than 90% in pdFVIII
preparations. In both cases we found a co-eluted
fibronectin 1 protein which is one of the most
abundant components in the blood plasma. Besides
the presence of fibronectin, both samples showed a
significant amount of inter-alpha inhibitor (IaI),
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Figure 2 - SDS-PAGE (7.5%) of reduced samples
(pdFVIII) according to Laemmli's17 method.
Protein are detected by Coomassie Brilliant
Blue.
Lane 1 HMW standard , Lane 2: 40 ug of
pdFVIII  Emoclot  ® 1000 UI/10 mL batch
KA0805 Kedrion,  Lane 3: 40 ug of pdFVIII
Beriate®  P1000 batch 81865011E CLS
Behring.
pre-alpha inhibitor (PaI) which represented the major
contaminant, together to fibrinogen and Kininogen.
Interestingly Emoclot® contained human IgM heavy
chain (spot 6) and in the same band we found FVIII,
which is very weak comparing to fibrinogen and vWF.
In Beriate®, it is interesting to underline that we
detected the presence galectin 3 binding protein
(G3BP), which co-eluted with FVIII. In this case we
are in presence of truncated form of FVIII revealed
by mass spectrometry as "Chain A, Crystal Structure
Analysis Of Coagulation FVIII"  with accession
number: gi|183448129.
Discussion
From our analysis, it came out that both Beriate®
and Emoclot® contained a large amount of vWF, as
well as of other plasma proteins such us fibrinogen,
fibronectin, and IgM heavy chain. This is not
surprising, since the production of pdFVIII
concentrates requires large plasma volumes and
includes several consecutive concentration and
purification steps using cryoprecipitation techniques,
and chromatographic steps, which reduce but not
eliminate all components of plasma. Several in vitro
studies have indicated that the presence of excess of
these plasma proteins, in addition to vWF, could
influence the function of cellular components of the
immune system19.
In particular, in agreement with Josic,20 in Beriate®
and Emoclot®  we have isolated IaIp as a by-product
of clotting of FVIII  from human plasma. IaIp are a
family of structurally-related serine protease inhibitors
which are found in relatively high concentrations in
human plasma. Recent studies have implicated a role
for IaIp in sepsis, and have demonstrated their
potential as biomarkers in sepsis and cancer, as IaIp
likely exert an important role in tumour invasion and
metastasis and in inflammation21.
Recently, a significant decrease of IaIp levels has
been shown in plasma of adult patients and newborns
with clinically-proven sepsis22,23.
Moreover, experimental animal studies have
demonstrated the beneficial effects of IaIp in
improving survival and halting the progression of
sepsis in adult animals24,25.
These results highlight the potential of IaIp as a
diagnostic and therapeutic agent22,24-28. However in this
specific case, during pdFVIII purification, they could
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Table I - List of protein identifications
Spot Protein name ID Mascot p/M r Number NCBI
number score % mathced Accession
peptides number
BERIATE
1 BE von Willebrand factor prepropeptide 5.44 1756 237661 53 gi|340361
2 BE inter-alpha (globulin) inhibitor H2 [Homo sapiens] 6.59 849 99813 29 gi|119585664
2 BE alpha-1-microglobulin; bikunin [Homo sapiens] 5.58 251 17215 5 gi|579676
3 BE inter-alpha (globulin) inhibitor H2 [Homo sapiens] 6.56 816 105606 20 gi|55958063
4 BE Chain A, Crystal Structure Analysis Of Coagulation 5.74 186 85365 4 gi|183448129
Factor VIII
4 BE galectin 3 binding protein [Homo sapiens] 5.13 285 66202 5 gi|5031863
5 BE Chain B, Crystal Structure Of Human Fibrinogen 8.31 819 55545 22 gi|237823915
6 BE kininogen 1 isoform 2 [Homo sapiens] 6.29 147 48936 3 gi|4504893
7 BE fibrinogen gamma chain [Homo sapiens] 5.61 293 50077 6 gi|182439
EMOCLOT
1 EMO von Willebrand factor preproprotein [Homo sapiens] 5.44 1665 237661 50 gi|340361
2 EMO von Willebrand factor prepropeptide 5.44 703 237661 20 gi|340361
3 EMO alpha-1-microglobulin; bikunin [Homo sapiens] 5.58 172 17215 3 gi|579676
3 EMO von Willebrand factor preproprotein [Homo sapiens] 5.30 782 322429 19 gi|89191868
4 EMO coagulation factor VIII, procoagulant component 6.51 73 239233 4 gi|171849087
(hemophilia A), isoform CRA_b [Homo sapiens] gi|119593052
4 EMO alpha-1-microglobulin; bikunin [Homo sapiens] 5.58 154 17215 3 gi|579676
5 EMO kininogen 1 isoform 2 [Homo sapiens] 6.29 486 48936 16 gi|4504893
6 EMO IGHM protein [Homo sapiens] 5.82 292 66032 7 gi|12804853
6 EMO alpha-fibrinogen precursor 8.26 250 70223 7 gi|182424
6 EMO B domain-deleted coagulation factor VIII 6.36 600 168754 16 gi|157863686
[synthetic construct]
7 EMO alpha-fibrinogen precursor 8.26 1166 70223 39 gi|182424
8 EMO beta-fibrinogen precursor 8.31 209 55545 6 gi|182430
9 EMO fibrinogen, beta chain preproprotein [Homo sapiens] 1311 56577 53 gi|70906435
10 EMO fibrinogen gamma chain [Homo sapiens] 5.61 480 50077 12 gi|182439
11 EMO fibrinogen gamma chain [Homo sapiens] 5.61 657 50077 17 gi|182439
11 EMO Chain B, Structure Of Complement C3b: 5.18 325 104912 8 gi|118137965
Insights Into Complement Activation And
Regulation
represent a protein burden to the patient and, in
improved pdFVIII preparations, protein
contaminations should be reduced as they may cause
an immunogenic response,29 as reported also by Josic
et al. 20. Hereby we showed that pdFVIII concentrates
contain a significant amount of foreign proteins which,
have been shown to be related to severe side reactions
in the recipient 30.
In Beriate®, we found G3BP which Bolsen et al.,31
claimed to be a potential contaminant  of recombinantly
produced factor IX .  G3BP is a secreted glycoprotein
present in the extracellular matrix of many tissues.
Galectins and their binding proteins have primarily
been described in cell-cell and cell-matrix interactions
involved in autoimmunity, inflammation and cancer
biology 32,33.
In the present study we found truncated form of
pdFVIII in Beriate® because of proteolytic process that
could be occurred during purification procedure30.
FVIII is sensitive to proteolysis34, and, therefore, it has
to be stabilized during the production process and in
the final formulation 34. Besides proteolysis,  most
serious complication is the development of inhibitor
antibodies most frequently at an early stage of therapy,
caused from truncated form of FVIII. These antibodies
are capable of blocking FVIII procoagulant activity35,36.
There have been dangerous outbreaks of inhibitors in
multitransfused patients in the past, and they seem to
Blood Transfus 2010; 8 Suppl 3:s98-s104  DOI 10.2450/2010.016S
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be due to the creation of neoepitopes in the FVIII
molecule during the manufacturing process 37-39.
In the present study, G3BP appears in the same
spot of  pdFVII due to the similar apparent molecular
weight, G3BP plays a role in cell apoptosis and have
relevant immunomodulatory activities given its role
in autoimmunity, tumour metastasis and inflammation.
This may be especially relevant in haemophiliacs as
these patients are often chronically infected with
hepatitis C and/or HIV and may be immuno-
compromised. Elevated G3BP levels in AIDS patients
seem to correlate with higher viral loads, especially
in haemophiliac HIV-positive patients 40-42. Therefore,
the presence of G3BP may have untoward effects on
the health of these patients.
In conclusion most pdFVIII concentrates contain
excess of plasma proteins which could influence the
function of cellular components of the immune
system19 and other contaminants, whose broad
biological effects could result in unforeseen consequences
in the recipients when infused for therapeutic purposes.
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